Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Holding KRON?
Track your performance easily
KRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.69 - $1.60
Previous Close$0.95
Volume24.55K
Average Volume (3M)82.11K
Market Cap
$57.28M
Enterprise Value-$52.23M
Total Cash (Recent Filing)$136.65M
Total Debt (Recent Filing)$27.13M
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Mar 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding60,294,610
10 Day Avg. Volume54,176
30 Day Avg. Volume82,114
Standard Deviation0.20
R-Squared0.20
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)6.81
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.21
Enterprise Value/Gross Profit-8.31
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$4.13Price Target Upside330.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Kronos Bio News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentKronos Bio announced having cleared the 80mg four-days-on, three-days-off dosing regimen for the CDK9i program and dosed the first patient in an expansion cohort focused on platinum-resistant, high-grade serous ovarian cancer.
Financial PerformanceR&D and SG&A expenses came in lower than prior estimates, indicating better cost management.
Product PipelineThe p300 KATi KB-9558 is on-track for IND submission by year-end, allowing for a first-in-human study in multiple myeloma in the first half of 2025.
Bears Say
Clinical TrialsKronos has decided to not move lanra forward into the Phase II portion of the Phase I/II trial of lanraplenib (lanra) + Xospata (gilteritinib) in r/r FLT3-mut AML.
Drug EfficacyWhile lanra's tolerability profile supported dose escalation up to 90mg with no DLTs, no complete responses or CRs with partial hematologic recovery (CRhs) were observed in any of the 24 evaluable patients.
Regulatory RisksRisks include failure to execute timely development of KB-0742 and inability to obtain regulatory approval for KB-0742.
---
Ownership Overview
30.18% Insiders
4.26% Mutual Funds
7.33% Other Institutional Investors
54.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.69 and its highest was $1.60 in the past 12 months.
What is Kronos Bio’s market cap?
Currently, no data Available
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is Mar 19, 2025 which is in 132 days.
How were Kronos Bio’s earnings last quarter?
Currently, no data Available
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Undervalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,294,610 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kronos Bio?
Among the largest hedge funds holding Kronos Bio’s share is Wildcat Capital Management, Llc. It holds Kronos Bio’s shares valued at 2M.
---
Kronos Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (330.66% Upside)
$4.13 (330.66% Upside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 955.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.26%
12-Months-Change
Fundamentals
Return on Equity
-63.01%
Trailing 12-Months
Asset Growth
-36.97%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Month Forecast
Average Price Target
$4.13
▲(330.66% Upside)
Technical Analysis
Best Analysts Covering KRON
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-36.51%
reiterated a buy rating 3 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -36.51% per trade.
---